Aptus Capital Advisors’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $36.8K | Buy |
24,853
+915
| +4% | +$1.35K | ﹤0.01% | 1204 |
|
|
2025
Q1 | $61.3K | Buy |
23,938
+575
| +2% | +$1.47K | ﹤0.01% | 1077 |
|
|
2024
Q4 | $43.9K | Buy |
23,363
+1,026
| +5% | +$1.93K | ﹤0.01% | 1116 |
|
|
2024
Q3 | $22.8K | Buy |
22,337
+1,412
| +7% | +$1.44K | ﹤0.01% | 1019 |
|
|
2024
Q2 | $24.5K | Buy |
20,925
+1,304
| +7% | +$1.53K | ﹤0.01% | 957 |
|
|
2024
Q1 | $24.7K | Buy |
19,621
+1,099
| +6% | +$1.39K | ﹤0.01% | 944 |
|
|
2023
Q4 | $33K | Buy |
18,522
+1,025
| +6% | +$1.82K | ﹤0.01% | 713 |
|
|
2023
Q3 | $29K | Buy |
17,497
+737
| +4% | +$1.22K | ﹤0.01% | 725 |
|
|
2023
Q2 | $33.5K | Buy |
16,760
+750
| +5% | +$1.5K | ﹤0.01% | 603 |
|
|
2023
Q1 | $33.6K | Buy |
+16,010
| New | +$33.6K | ﹤0.01% | 593 |
|
|
2022
Q4 | – | Sell |
-13,957
| Closed | -$15K | – | 831 |
|
|
2022
Q3 | $15K | Buy |
13,957
+1,539
| +12% | +$1.65K | ﹤0.01% | 631 |
|
|
2022
Q2 | $14K | Buy |
12,418
+967
| +8% | +$1.09K | ﹤0.01% | 549 |
|
|
2022
Q1 | $12K | Buy |
+11,451
| New | +$12K | ﹤0.01% | 586 |
|
|
2019
Q4 | – | Sell |
-3,638
| Closed | -$7K | – | 498 |
|
|
2019
Q3 | $7K | Hold |
3,638
| – | – | ﹤0.01% | 402 |
|
|
2019
Q2 | $17K | Buy |
+3,638
| New | +$17K | ﹤0.01% | 318 |
|